TRIM44 Antibody

What is the basic structure of TRIM44 protein?

TRIM44 is an atypical TRIM family protein that contains an N-terminal ubiquitin hydrolase-type zinc-finger domain, followed by a coiled-coil domain, a zinc-finger B-box homology domain, and a second coiled-coil domain near the C-terminus . Unlike typical TRIM family proteins, TRIM44 lacks the RING finger domain that normally provides E3 ubiquitin ligase activity . TRIM44's calculated molecular weight is 38 kDa (344 amino acids), but the observed molecular weight in experimental conditions is typically between 50-55 kDa .

What cellular functions has TRIM44 been associated with?

TRIM44 has been implicated in multiple biological processes:

• Regulation of protein degradation pathways by connecting the ubiquitin-proteasome system (UPS) with autophagy degradation pathways

• Cell proliferation and migration in various cancer types

• Antiviral immune response by stabilizing virus-induced signaling adaptor (VISA)

• Possible role in the differentiation and maturation of neuronal cells

• Negative regulation of PAX6 expression

• Enhancement of NF-κB signaling in cancer cells

What are the recommended applications and dilutions for TRIM44 antibodies?

Different TRIM44 antibodies have been validated for various applications. Based on the available data, the recommended applications and dilutions are:

It is recommended to titrate these antibodies in each testing system to obtain optimal results, as the ideal dilution may be sample-dependent .

What are the recommended antigen retrieval methods for TRIM44 immunohistochemistry?

For immunohistochemical detection of TRIM44, the following antigen retrieval methods have been reported:

• TE buffer pH 9.0 is the suggested primary method for human gliomas tissue samples

• Alternatively, citrate buffer pH 6.0 can also be used

• Heating sections in a water bath at 100°C for 60 min in a 10 mM sodium citrate buffer (pH 6.0) has been successfully used in breast cancer tissue samples

• For cervical cancer tissue, heating sections in a stainless autoclave has been reported

The optimal antigen retrieval method may vary depending on tissue type and fixation conditions, so optimization is recommended for specific experimental settings.

How is TRIM44 implicated in cancer progression and what cellular mechanisms are involved?

TRIM44 overexpression has been linked to poor prognosis in multiple cancer types. Several studies have elucidated the mechanisms behind TRIM44's oncogenic properties:

In breast cancer:

In testicular germ cell tumors:

• Gain-of-function studies showed that overexpression of TRIM44 promoted cell proliferation and migration of NTERA2 and NEC8 cells

• Knockdown of TRIM44 promoted apoptosis and repressed cell proliferation and migration

• Microarray analysis revealed that tumor suppressor genes (CADM1, CDK19, PRKACB) were upregulated in TRIM44-knockdown cells

In cervical cancer:

How does TRIM44 interact with protein degradation pathways?

TRIM44 serves as a novel link between the ubiquitin-proteasome system (UPS) and autophagy degradation pathways . Key findings include:

• TRIM44 colocalizes with ubiquitin-positive CFTRΔF508 protein aggregates but not with ubiquitin-deficient aggresomes (GFP-250)

• TRIM44 expression decreases the number of cells containing aggregates induced by proteasome inhibitors (bortezomib, MG132)

• Knockdown of TRIM44 increases the number of cells containing aggregates

• TRIM44 expression confers resistance to bortezomib-induced cell death in multiple myeloma cells

• TRIM44 likely removes aggregates through direct binding to ubiquitin-positive protein aggregates

The experimental evidence suggests that TRIM44 may function in ubiquitin-dependent protein quality control by promoting the clearance of protein aggregates through autophagy, particularly when the UPS is impaired.

What is the role of TRIM44 in antiviral immunity?

TRIM44 plays a significant role in enhancing antiviral responses through the following mechanisms:

• TRIM44 interacts with virus-induced signaling adaptor (VISA), a critical adaptor in the regulation of type I IFN production

• Overexpression of TRIM44 enhances cellular response to viral infection, while knockdown diminishes this response

• TRIM44 stabilizes VISA by preventing its ubiquitination and degradation

• This stabilization enhances VISA-mediated signaling pathways, leading to activation of transcription factors like NF-κB and IRF3

These findings indicate that TRIM44 functions as a positive regulator of the virus-triggered immune response by enhancing the stability of VISA, which is crucial for antiviral signaling.

How can I validate TRIM44 antibody specificity in my experimental system?

To ensure TRIM44 antibody specificity, consider the following validation approaches:

• Positive and negative controls:

  • Use tissues known to express TRIM44 as positive controls (e.g., mouse testis tissue, human liver tissue)

  • Use TRIM44 knockout or knockdown cells as negative controls

• Multiple antibody comparison:

  • Compare results using antibodies from different sources or raised against different epitopes

  • Confirm the observed molecular weight (typically 50-55 kDa for TRIM44)

• Overexpression validation:

  • Use cells transfected with TRIM44 expression vectors as additional positive controls

  • Compare the band pattern with non-transfected cells

• Immunoprecipitation followed by Western blot:

  • Perform immunoprecipitation with one TRIM44 antibody and Western blot with another to confirm target specificity

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing peptide to block specific binding sites

How should I interpret discrepancies in TRIM44 detection between different antibodies or experimental approaches?

When faced with discrepancies in TRIM44 detection:

• Consider epitope accessibility:

  • Different antibodies target different epitopes that may be differentially accessible depending on protein conformation, post-translational modifications, or interaction partners

  • Polyclonal antibodies (e.g., 11511-1-AP) recognize multiple epitopes, while monoclonal antibodies (e.g., 66249-1-PBS, ab236422) recognize single epitopes

• Cross-reactivity assessment:

  • Evaluate potential cross-reactivity with other TRIM family members, which share structural similarities

  • Validate results using alternative methods like RT-PCR to confirm mRNA expression levels

• Post-translational modifications:

  • Consider that the discrepancy might reflect different post-translational modifications of TRIM44 in different contexts

  • The calculated molecular weight of TRIM44 is 38 kDa, but its observed weight is 50-55 kDa, suggesting post-translational modifications

• Fixation and antigen retrieval impacts:

  • For immunohistochemistry, different fixation methods and antigen retrieval techniques can significantly affect antibody binding

  • Compare multiple antigen retrieval methods if discrepancies are observed in IHC experiments

How can I design experiments to study TRIM44's role in specific signaling pathways?

When designing experiments to investigate TRIM44's involvement in signaling pathways:

• For NF-κB signaling:

  • Measure phosphorylation of p65 and IκBα after TRIM44 overexpression or knockdown using Western blot

  • Use NF-κB luciferase reporter assays to assess NF-κB transcriptional activity

  • Stimulate cells with TNFα to activate the pathway and observe TRIM44-dependent effects

• For antiviral signaling:

  • Assess type I IFN production using reporter assays or ELISA after viral infection in TRIM44-manipulated cells

  • Examine the stability and ubiquitination status of VISA in TRIM44-overexpressing or knockdown cells

  • Challenge cells with various RNA viruses to determine virus-specific effects

• For protein degradation pathways:

  • Induce protein aggregation using proteasome inhibitors like bortezomib or MG132

  • Quantify aggregate formation using fluorescence microscopy and analyze colocalization with TRIM44

  • Assess autophagy markers (LC3-II, p62) in relation to TRIM44 expression levels

What are the methodological considerations for studying TRIM44's interaction with binding partners?

When investigating TRIM44's protein-protein interactions:

• Co-immunoprecipitation approaches:

  • Use antibodies against different domains of TRIM44 to identify domain-specific interactions

  • Consider native versus crosslinked conditions to capture transient interactions

  • Use reciprocal co-IPs to confirm interactions (pull down with partner antibody and detect TRIM44, and vice versa)

• Subcellular localization studies:

  • Perform subcellular fractionation followed by Western blot to determine compartment-specific interactions

  • Use confocal microscopy to visualize colocalization with potential binding partners

  • Consider live cell imaging to capture dynamic interactions

• Domain mapping:

  • Generate truncated versions of TRIM44 to identify interaction domains

  • Use site-directed mutagenesis to disrupt specific protein interfaces

  • Consider in vitro binding assays with recombinant domains to confirm direct interactions

• Proximity labeling approaches:

  • Use BioID or APEX2 fusions with TRIM44 to identify proteins in close proximity in living cells

  • Validate potential interactions identified through proximity labeling with alternative methods